

References

I-194

1. Muntoni F, Frank D, Sardone V, et al. Golodirsen Induces Exon Skipping Leading to Sarcolemmal Dystrophin Expression in Duchenne Muscular Dystrophy Patients With Mutations Amenable to Exon 53 Skipping (S22.001). *Neuro*. 2018;90(15 Supplement)
2. Vyondys 53TM (golodirsen) [package insert]. Cambridge, MA. Sarepta Therapeutics, Inc. 2019.
3. Clinical Pharmacology Compendia. [database online]. 2019 Tampa FL: Gold Standard, Inc. Golodirsen.